Eli Lilly continued its non-opioid pain acquisition sprint by buying 4E Therapeutics, adding early-stage MNK inhibitor programs designed to target chronic pain without addiction risk. 4E’s lead candidate 4ET1103 has completed early human safety evaluation, and the company’s pipeline includes assets aimed at neuropathic pain, migraine, and acute pain. Lilly’s broader M&A strategy remains consistent—following earlier pain-sector buys and in the context of prior acquisitions spanning sleep disorder medicines and other modalities. The acquisition also highlights that large pharmas are still willing to absorb early-stage scientific and clinical uncertainty when the target biology is differentiated. For the sector, it signals sustained appetite for novel, non-opioid mechanisms in chronic pain, even as developers navigate historical pain-program attrition.